Skip to main content

pivekimab sunirine

·Code: IMGN632, PVEK

pivekimab sunirine: 3 clinical trials tracked.

pivekimab sunirine evidence translation

What we can confirm

3 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about pivekimab sunirine, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

Acute Myeloid Leukemia
Clinical Trial Registry Records (3)

A Randomized Phase 2/3 Study Evaluating the Safety and Efficacy of Pivekimab Sunirine (PVEK) in Combination With Venetoclax and Azacitidine in Adult Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible to Receive Intensive Chemotherapy

NCT07581002Registry updated 2026-10-02·Phase 2/Phase 3·ABBV
Recruiting

Primary endpoint: Phase 2: Complete remission (CR)

InterventionalRandomizeddouble660 targetStarted 2026-06Completion 2032-0636 sites · Austria, France, Israel, South Korea…AbbVie

A Phase 1b Study of the Safety and Pharmacokinetics of Pivekimab Sunirine in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT07306832Registry updated 2026-10-05·Phase 1·ABBV
Recruiting

Primary endpoint: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) Leading to Treatment Discontinuation

Interventionalopen18 targetStarted 2026-05Completion 2030-0314 sites · Australia, France, Italy, South Korea…AbbVie

Phase 1 Study of FLAG-Ida With Pivekimab Sunirine (PVEK) for Adults With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

NCT06034470Registry updated 2026-07-29·Phase 1
Active, not recruiting

Primary endpoint: Incidence of dose-limiting toxicities during cycle 1

Interventionalopen30 enrolledStarted 2023-12Completion 2029-051 site · United StatesFred Hutchinson Cancer Center